These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1026071)

  • 1. [Treatment of prostatic cancer with progestational agents].
    Bouffioux C
    Acta Urol Belg; 1976 Oct; 44(4):336-53. PubMed ID: 1026071
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of advanced prostatic carcinoma with medroxyprogesterone.
    Rafla S; Johnson R
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):261-7. PubMed ID: 4208339
    [No Abstract]   [Full Text] [Related]  

  • 3. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
    Flamm J; Spona J
    Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of prostatic cancer with hormonal control on the diencephalo-hypophyseal arch].
    Ferulano O; Petraroia F; Castaldo A
    Minerva Urol; 1972; 24(6):274-80. PubMed ID: 4614057
    [No Abstract]   [Full Text] [Related]  

  • 7. [Histological modifications in carcinoma of the prostate during treatment with medroxyprogesterone acetate].
    Costa V; Ferreli A; Valdès E; Usai E
    Pathologica; 1979; 71(1016):845-9. PubMed ID: 262299
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Carcinoma of the prostatic utricle treated with medroxyprogesterone].
    Sundblad AS; Rodríguez Consoli J
    Medicina (B Aires); 1984; 44(1):105. PubMed ID: 6535902
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of spirogermanium in metastatic prostate cancer.
    Dexeus FH; Logothetis C; Samuels ML; Hossan B
    Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
    [No Abstract]   [Full Text] [Related]  

  • 11. [Estracyt treatment in prostatic neoplasms].
    Sander S
    Tidsskr Nor Laegeforen; 1976 Jan; 96(1):27-8. PubMed ID: 1257949
    [No Abstract]   [Full Text] [Related]  

  • 12. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
    Jones WG; Fosså SD; Bono AV; Klijn JG; De Pauw M; Sylvester R
    Cancer Treat Rep; 1987 Dec; 71(12):1317-8. PubMed ID: 3480046
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
    Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cancer of the prostate: new hormone therapies].
    Namer M; Boublil JL; Kather R; Cavaglione G
    Bull Cancer; 1986; 73(1):47-55. PubMed ID: 3779122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 16. Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.
    Pannuti F; Martoni A; Pollutri E; Camera P; Losinno F; Giusti H
    Panminerva Med; 1976; 18(3-4):129-36. PubMed ID: 176620
    [No Abstract]   [Full Text] [Related]  

  • 17. M-AMSA in disseminated prostatic carcinoma: a phase II study.
    Drelichman A; Decker DA; Al-Sarraf M; Dhabuwala CB
    Cancer Treat Rep; 1982 Nov; 66(11):1993-4. PubMed ID: 6897206
    [No Abstract]   [Full Text] [Related]  

  • 18. A preliminary report of mitotane therapy of advanced renal and prostate cancer.
    Hogan TF; Citrin DL; Freeberg BL
    Cancer Treat Rep; 1981; 65(5-6):539-40. PubMed ID: 7237479
    [No Abstract]   [Full Text] [Related]  

  • 19. Criteria for response to treatment of metastatic prostatic cancer.
    Newling DW
    Prog Clin Biol Res; 1985; 185A():205-20. PubMed ID: 3898130
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.